NovaBay Pharmaceuticals, Inc.
NBY
$0.6001
$0.00010.02%
AMEX
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -6.77% | -20.01% | -27.75% | -20.03% | -27.26% |
| Total Other Revenue | -- | -77.50% | -95.00% | -100.00% | -100.00% |
| Total Revenue | -6.45% | -20.21% | -27.95% | -20.22% | -27.42% |
| Cost of Revenue | -24.50% | -33.01% | -40.71% | -24.28% | -33.99% |
| Gross Profit | 6.53% | -10.27% | -17.91% | -17.05% | -21.82% |
| SG&A Expenses | 12.42% | -13.77% | -18.96% | -24.84% | -33.59% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.36% | -19.76% | -26.17% | -25.05% | -34.08% |
| Operating Income | -21.26% | 18.85% | 21.87% | 34.85% | 46.59% |
| Income Before Tax | -17.33% | 39.79% | 32.13% | 33.37% | 42.07% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -17.33% | 39.79% | 32.13% | 33.37% | 42.07% |
| Earnings from Discontinued Operations | 99.63% | -127.22% | -315.53% | -718.53% | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 25.07% | 26.34% | 11.99% | 9.16% | 9.13% |
| EBIT | -21.26% | 18.85% | 21.87% | 34.85% | 46.59% |
| EBITDA | -21.80% | 17.29% | 18.81% | 31.75% | 43.71% |
| EPS Basic | 94.61% | 77.58% | 81.24% | 69.55% | 59.55% |
| Normalized Basic EPS | 91.79% | 84.22% | 70.42% | 62.15% | 35.10% |
| EPS Diluted | 94.61% | 77.58% | 81.24% | 69.55% | 59.55% |
| Normalized Diluted EPS | 91.79% | 84.22% | 70.42% | 62.15% | 35.10% |
| Average Basic Shares Outstanding | 2,724.84% | 1,610.26% | 779.92% | 460.42% | 161.12% |
| Average Diluted Shares Outstanding | 2,724.84% | 1,610.26% | 779.92% | 460.42% | 161.12% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |